On October 1, 2021 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, reported that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 10-14, 2021 in Washington, DC (Press release, IMV, OCT 1, 2021, sec.gov/Archives/edgar/data/1734768/000117625621000258/exhibit99-1.htm [SID1234590623]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Title: Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
Presenter:
Oliver Dorigo, M.D., Ph.D.,
Director and Associate Professor
Division Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University, CA
Poster Number: 353
Important dates
November 9, 2021: Full abstracts are made public at 8 a.m. EST
November 12, 2021: Poster presentation
Poster Hall Hours: 7 a.m.–8:30 p.m.
Dr. Dorigo will be present in person at lunch time (12:40–2:10 p.m. EST) and during the poster reception (7–8:30 p.m. EST)
November 12, 2021: Poster and e-poster presentation will be available under the Scientific Publications & Posters section on IMV’s website.